What is breast implant rupture?

Rupture is a tear or hole in the implant shell. Modern silicone gel implants use cohesive gel that tends to stay in place even after rupture — unlike older liquid silicone implants — but rupture still requires evaluation and usually surgical management.

What is the difference between intracapsular and extracapsular rupture?

Intracapsular rupture means the gel stays within the natural capsule around the implant — this is the most common pattern for cohesive gel implants. Extracapsular rupture means the gel has migrated beyond the capsule into surrounding tissue, lymph nodes, or further. Extracapsular rupture is generally considered an indication for prompt surgical management.

What is Silent Rupture?

Silent Rupture refers to implant rupture without obvious symptoms. Because cohesive gel does not migrate significantly in many intracapsular ruptures, patients may not notice anything. This is why the U.S. FDA recommends imaging surveillance for silicone gel implants — currently MRI screening starting 5-6 years post-op and every 2-3 years thereafter, or serial high-resolution ultrasound as an alternative per surgeon recommendation.

How is rupture diagnosed?

MRI is the most sensitive imaging modality for silicone implant rupture (approximately 89-94% sensitivity in published series). High-resolution ultrasound is widely used as a first-line screening tool (approximately 70-74% sensitivity in published series). Mammography has limited utility for rupture detection. The optimal modality depends on patient factors and surgeon judgment.

What are the treatment options for rupture?

Options include implant exchange (most common — replace with a new implant), explant only (remove implant without replacement), and en-bloc capsulectomy if rupture is associated with significant capsular changes or to assess for late seroma / BIA-ALCL workup. The specific plan is individualized based on rupture type, capsule status, and patient preference.

Complications

Breast Implant Rupture — Symptoms, Diagnosis, and Treatment

UNE Plastic Surgery · Dr. Kim Uigeon, board-certified plastic surgeon · Published 2026-05-15

Breast implant rupture is one of the long-term outcomes that requires ongoing surveillance after augmentation. This article explains the types (intracapsular vs extracapsular), the concept of Silent Rupture, available imaging modalities (ultrasound vs MRI), FDA guidance on imaging schedules, and surgical revision options.

1. Rupture Types

Type	Description	Typical Management
Intracapsular Rupture	Shell tear, gel remains within the natural capsule.	Scheduled surgical revision.
Extracapsular Rupture	Gel has migrated beyond the capsule into surrounding tissues or lymph nodes.	Prompt surgical evaluation; revision typically recommended.

Modern cohesive gel implants tend to keep gel in place even after rupture — the gel does not flow like older liquid silicone implants. This is why many ruptures are intracapsular rather than extracapsular.

2. Symptoms

Visible shape change, asymmetry, or contour irregularity.
Change in firmness — softening, hardening, or new palpable nodules.
Persistent pain or discomfort.
Same-side axillary lymphadenopathy (rare).
Many ruptures are Silent Rupture — no symptoms, detected only on imaging.

3. Silent Rupture

Because cohesive gel often does not migrate significantly after rupture, many ruptures produce no symptoms. This concept of Silent Rupture is the basis for routine imaging surveillance.

Current U.S. FDA guidance for silicone gel implants:

MRI screening starting 5-6 years after surgery.
Then MRI every 2-3 years thereafter.
Or serial high-resolution ultrasound as an alternative per surgeon judgment.

Patients should follow the imaging schedule that their surgeon recommends based on individual factors.

4. Imaging Modalities

Modality	Sensitivity (Published)	Specificity	Notes
MRI	~89-94%	~90-94%	Considered the reference standard for rupture detection.
High-resolution Ultrasound	~70-74%	~55-92%	First-line screening; no radiation; can be repeated.
Mammography	Low for rupture	—	Limited utility for rupture detection in the presence of implants.
CT	Not preferred	—	Not first-line for rupture.

5. Manufacturer Rupture Data (General)

Reported rupture rates vary by study methodology, follow-up length, and patient population. As general orientation only:

Mentor MemoryGel Smooth (FDA Core Study, 10-year): rupture rate approximately 7.7% primary augmentation cohort.
Motiva (manufacturer + independent series): published low rupture rates with the TrueMonobloc multi-layer shell technology, with follow-up shorter than Mentor's longest series.

Individual rupture risk is influenced by trauma history, surgical handling, mechanical load over time, and patient factors — not shell choice alone.

6. Surgical Revision Options

Implant exchange (most common)

Remove the ruptured implant, clean any gel residue, assess the capsule, and place a new implant. Often combined with a change in surface technology (e.g., from textured to smooth or nano-textured).

Capsulectomy

If capsule changes are significant — calcification, thickening, or BIA-ALCL workup — total or en-bloc capsulectomy is often combined with implant removal.

Explant only

Some patients elect to remove implants without replacement. Tissue support after explant depends on prior implant size, soft-tissue elasticity, and time since the original surgery. Mastopexy (lift) may be added based on tissue status.

Same-stage adjustments

Rupture revision is also an opportunity to address any concurrent issues: capsular contracture, malposition, asymmetry, double bubble, bottoming out. Combining corrections in a single surgery is often clinically appropriate.

7. Does Rupture Cause Cancer?

There is no established causal link between silicone gel implant rupture and breast cancer. A separate, distinct long-term concern is BIA-ALCL (breast-implant-associated anaplastic large-cell lymphoma), which has been associated primarily with certain textured implants and is unrelated to rupture per se. Patients with prior textured implants may be advised to undergo specific surveillance per current guidelines.

8. When to Seek Evaluation

Visible shape change, asymmetry, or new firmness.
Persistent pain or discomfort.
Sudden swelling or new lumps.
Scheduled imaging due (per surgeon recommendation).
Suspected late seroma (especially in patients with textured implants).

Medical disclaimer. Results, recovery time, pain, swelling, and scar appearance vary depending on each patient's anatomy, tissue condition, surgical plan, and healing process. Imaging schedules and revision options should be discussed with a board-certified surgeon and verified against current FDA and manufacturer guidance.

— Dr. Kim Uigeon (Board-certified plastic surgeon, Republic of Korea · UNE Plastic Surgery)